Menu

SIMDAX® (i.v. levosimendan)

SIMDAX® (i.v. levosimendan) is an inodilator (calcium sensitizer and potassium channel opener) indicated for the short-term treatment of acutely decompensated severe chronic heart failure (ADHF) in situations where conventional therapy is not sufficient, and in cases where inotropic support is considered appropriate.

To find out more, click on the section About SIMDAX®. If you are a healthcare professional, you can register as a user in the section for healthcare professionals for full information on SIMDAX®.

Prescribing information

SIMDAX® is indicated for the short-term treatment of acutely decompensated severe chronic heart failure (ADHF) in situations where conventional therapy is not sufficient, and in cases where inotropic support is considered appropriate. Read more.

Register here

Our section for healthcare professionals provides additional and useful information, including several videos, on SIMDAX®. Join us and register here


1. Nieminen MS et al. Eur Heart J Suppl. 2017;19(suppl C);C15-C21
2. Papp Z et al. Int J Cardiol. 2012;159:82–87.

Read more


Web-cam image
 Click HERE for program on Aug 29 


Acute and Advanced Heart Failure Knowledge Center »
 


Levosimendan in Wikipedia »


LeodorTrial logo image file
Repetitive Levosimendan infusions for patients with advanced chronic heart failure »

 

Blog on Acute and Advanced Heart Failure »

Prof Pölzl's blog about therapeutic options for Acute and Advanced Heart Failure

Prof G Pölzl 

Prescribing information

Simdax® is indicated for the short-term treatment of acutely decompensated severe chronic heartfailure (ADHF) in situations where conventional therapy is not sufficient, and in cases where inotropic support is considered appropriate. Read more.

Register here

Our section for healthcare professionals provides additional and useful information, including several videos, on Simdax®. Join us and register here.